FIELD: medicine.
SUBSTANCE: this invention relates to the use of anti-HER2 antibody-drug conjugate (ADC) to obtain a drug for the treatment of urothelial carcinoma.
EFFECT: drug is safe and effective for patients with urothelial carcinoma, especially locally spread or metastatic urothelial carcinoma, and can effectively prolong the survival time of patients.
8 cl, 8 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | 2020 |
|
RU2795196C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| POLYSPECIFIC ANTIBODIES | 2009 |
|
RU2547596C2 |
| HUMANISED ANTIBODIES TO LIV-1 AND USE THEREOF FOR TREATING CANCER | 2011 |
|
RU2608646C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2009 |
|
RU2553566C2 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2008 |
|
RU2511410C2 |
| HUMANIZED ANTIBODIES TO THE THOMSEN-FRIEDENREICH ANTIGEN | 2015 |
|
RU2699717C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
